Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Marizomib - Celgene Corporation

Drug Profile

Marizomib - Celgene Corporation

Alternative Names: CC-92763; MRZ; NPI-0052; Salinosporamide A

Latest Information Update: 26 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nereus Pharmaceuticals
  • Developer Canadian Cancer Trials Group; Celgene Corporation; European Organisation for Research and Treatment of Cancer; National Cancer Institute (USA); Triphase Accelerator Corporation
  • Class Anti-inflammatories; Antineoplastics; Lactones; Pyrroles; Small molecules
  • Mechanism of Action Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glioblastoma
  • Phase II Ependymoma; Multiple myeloma
  • No development reported Diffuse intrinsic pontine glioma; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 26 Feb 2024 Dana-Farber Cancer Institute terminates phase I trial in Diffuse intrinsic pontine glioma (In children, In adults, In adolescents, Monotherapy, Second-line therapy or greater) in USA (PO) due to withdrawal of support from BMS (NCT04341311)
  • 14 Feb 2024 Dana-Farber Cancer Institute terminates phase I trial in Glioma (In children, In adults, In adolescents, Combination therapy, Second-line therapy or greater) in USA (PO) due to withdrawal of support from BMS (NCT04341311)
  • 28 Sep 2023 No recent reports of development identified for phase-I development in Diffuse intrinsic pontine glioma(Combination therapy, In adolescents, In children, Second-line therapy or greater, In adults) in USA (IV, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top